Is independent prescribing worth it for your pharmacy?

For those pharmacies that already have an independent prescriber, the monthly infrastructure payment should cover real costs rather than creating them. There is no need to fund any training, nor recruit anyone new. However, that doesn’t mean this option is completely cost-free.

Even existing prescribers may need time to build confidence in new pathways, and employers must ensure they work within their competence. There will also be less time for dispensing, meaning backfill elsewhere in the team.

Indicative cost position

The figures below are illustrative estimates only. Actual costs will vary by location, staffing model, local rates, availability of prescribers and the level of supervision or backfill needed.

One-off cost: Minimal, largely covered by the £500 set-up payment.

Recurring cost: Indicative indemnity uplift, plus the cost of the pharmacist’s time spent delivering IP consultations. If that time needs to be fully backfilled, at 10 consultations a week and an illustrative £30 an hour of locum-equivalent cover, this could amount to broadly £3,000 to £5,000 a year, depending on consultation volumes and local rates.

Marginal revenue at medium utilisation: Around £15,100 (£6,300 infrastructure payment + £8,800 in consultation fees).

Net: Potentially the strongest position. Positive at medium utilisation even after backfilling. Payback close to immediate.

From September 2026, newly qualified pharmacists will register as independent prescribers from day one. Expect more competition to secure them, including from general practice.

A newly qualified prescriber brings both a capability and a confidence risk. They cannot deliver every pathway immediately, and there is a set requirement for supervised learning during training, so budget mentoring time before they are cost neutral.

Employing someone new purely for this is a significant investment, and the funding is only confirmed for 2026/27. Future funding will depend on the next contract.

Cost of recruiting a prescriber

One-off costs: Recruitment agency fees are typically around 15-20% of first-year salary. On an illustrative £45,000-£50,000 salary, that would be around £6,750 to £10,000, + a mentoring ramp of three to six months of reduced early productivity.

Recurring cost: As an indication, community pharmacist salaries are typically £38,000 to £55,000, with prescribing roles usually towards the top of that range. Dedicated IP or prescribing-led roles can reach £50,000 to £65,000+, especially where they include clinical service leadership. A realistic premium over a non-prescribing pharmacist may be £5,000 to £10,000 a year, but this will depend on local hiring conditions.

If the prescriber is a net new hire mainly for IP, the marginal cost could be closer to a full salary, illustratively £45,000 to £55,000. At that level, the £6,300 infrastructure payment and consultation income only stack up at high, sustained volume.

Net: Viable, and relatively quick to pay back, if you are upgrading an existing role. Harder to justify at low utilisation if it means adding a new salary to the cost base.

For pharmacies without an IP, training an existing pharmacist keeps the most control, but it is still an investment, not just funded training. A GPhC-accredited course usually takes around six months part-time and includes at least 12 days, or 90 hours, of supervised practice with a designated prescribing practitioner (DPP).

For many pharmacists, tuition will not be the main cost. NHS England has opened funded IP places for 2026/27, with fees paid directly to the university and course start dates available up to March 2027. These places are likely to be competitive, so pharmacists should apply early and secure a DPP and suitable practice-based learning setting before committing.

The real cost is time out of the pharmacy. Funding covers course fees only, not the pharmacist’s course time or DPP supervision, so the cost sits in backfill and finding supervision, which should be secured before committing as it is often the main bottleneck.

Training is not necessarily the weakest option. You keep someone who knows the team, patients and business, even if there is disruption while they’re getting their qualification.

Cost of training

One-off cost: Tuition is £0 with an NHS England-funded place, or £1,800 to £3,300 self-funded, with no retrospective reimbursement.

Backfill: Study days plus the 90 hours of supervised practice mean roughly 15 to 20 days of cover. At £200 to £280 a day, that adds £3,000 to £5,600, taking the realistic one-off total to about £3,000 to £6,000 with a funded place, or £5,000 to £9,000 if self-funding.

Tax treatment: In many cases, training that updates or adds skills within an existing trade will be an allowable business expense, while unrelated new-trade training may not be. The position should be checked against the pharmacy’s specific circumstances before committing.

Recurring cost once qualified: The same displaced-time and backfill costs as the “already have an IP” route.

Net: Higher upfront cost than the other two routes, then broadly the same steady-state economics. The £6,300 infrastructure payment nearly covers the one-off cost in year one, so payback should be within the first year at medium utilisation and longer at low utilisation. The main advantage is that the pharmacist is already loyal, embedded and known to the business.